BURLINGTON, Mass., Sept. 18, 2015 /PRNewswire/ -- Decision Resources Group finds that while some differences exist, the spinal implant markets in both the US and Europe will continue to expand, owing to several factors including the adoption of premium-priced motion preserving devices, favorable population dynamics, the continual emergence of supporting clinical data, and device innovation--especially related to minimally invasive spine surgeries. Still, purchasing will be limited to some extent by cost-containment measures that affect facility budgets. Moreover, stringency with reimbursement coverage and an increasing emphasis on conservative care will hinder market potential.

Other key findings from the Decision Resources Group's Medtech 360 spinal implant reports:

  • The ongoing emergence of robotic spine surgery will drive procedures in the long term due to the associated benefits of robotic surgery; these include a reduction in blood loss, postoperative pain, narcotics, surgeon tremor, and hospital stay associated with spinal implant procedures. However, robotic spine surgery will continue to be limited by obstacles such as limited accessibility, high cost, and a lack of surgeon training in the near term.
  • Although additive manufacturing, also known as 3-D printing, has not yet disrupted the spinal implant market, the technology will affect market dynamics to some extent in the future. Patient-specific device customization and flexibility with the application of osteoinductive coatings are among the early applications that demonstrate the potential of this technology in spinal implant markets.
  • A few novel innovations pose noteworthy long-term threat to spinal implant markets. In particular, there are ongoing clinical trials that focus on the investigation of biologics that show the potential to regenerate vertebral discs. If these products prove effective, the disruptive impact on spinal implant markets could be potentially significant.

Comments from Decision Resources Group Team Lead Rene Azeez:

  • "Regenerative medicine represents an important part of the future of spine treatment. In my opinion, spinal implant companies will have to be flexible in the way they look at their current portfolios. I don't think that traditional implants will disappear, but I do believe that regenerative therapies will take more of the center stage in the treatment of spinal pathologies in the years to come."
  • "Another big shift in spine surgery is where the procedures are being performed. Reimbursement, patient preference, surgeon motive, and a myriad of other factors have driven the choice between hospital inpatient, hospital outpatient, and ASCs to become increasingly complex. Spinal implant firms are a major stakeholder in this decision, and their strategic platform should heavily consider site of service trends in spine surgeries."

For more information on purchasing this report, please email questions@teamDRG.com.

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 14 global locations. DRG provides the pharmaceutical, biotech, medical device, financial services and payer industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. DecisionResourcesGroup.com.

Media contact:

SHIFT Communications 
Theresa Masnik 
617.779.1871 
dresources@shiftcomm.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

 

SOURCE Decision Resources Group

German Rheumatologists and Gastroenterologists Say They Are Not Under Pressure to Switch Patients on Remicade to Infliximab Biosimilars

View Now